Health care experts provide insights into patient education, shared decision-making, and treatment monitoring in DLBCL (diffuse large B cell lymphoma) therapies, reviewing education strategies and response monitoring.
Discover strategies for minimizing adverse events and overlapping toxicities in patients undergoing lenvatinib and pembrolizumab therapy for recurrent endometrial cancer.
Patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy reported higher quality of life and were less likely to experience vomiting when receiving fosaprepitant every week as opposed to every three weeks.